FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950240845> ?p ?o ?g. }

• W2950240845 endingPage "4408" @default.
• W2950240845 startingPage "4391" @default.
• W2950240845 abstract "Rationale: Current therapies for hepatocellular carcinoma (HCC) are hampered by treatment failure and recurrence due to the remaining treatment-resistant liver cancer stem cells (CSCs). Stemness and epithelial-mesenchymal transition (EMT) are regarded as two fundamental characteristics of liver CSCs necessary for cancer progression; thus, drugs that simultaneously target both characteristics should prove effective in eliminating HCC and impeding recurrence. In this study, we developed new arsenic trioxide (ATO)-based nanoparticles (NPs), which are expected to be more effective than the current HCC therapy, and explored their potential mechanism. Methods: A one-pot reverse emulsification approach was employed to prepare the ZnAs@SiO2 NPs. HCC cell lines, MHCC97L and Hep3b, were used to analyze the antitumor activity of ZnAs@SiO2 NPs in vitro and in vivo by quantifying cell growth and metastasis as well as to study the effect on stemness and EMT. SHP-1 siRNA was used to validate the role of the SHP-1/JAK2/STAT3 signaling pathway in mediating inhibition of stemness and EMT by ZnAs@SiO2. Results: Compared with the current ATO treatment, ZnAs@SiO2 NPs promoted apoptosis and significantly inhibited proliferation, migration, and invasion of both MHCC97L and Hep3b cells. In the in vivo assay, ZnAs@SiO2 NPs inhibited tumor growth by 2.2-fold and metastasis by 3.5-fold as compared to ATO. The ZnAs@SiO2 NPs also inhibited tumor spheroid formation in vitro and tumor initiation in vivo and induced significant changes in the expression of stemness markers (CD133, Sox-2, and Oct-4) and EMT markers (E-cadherin, Vimentin, and Slug) both in vitro and in vivo. These effects of ZnAs@SiO2 that correlated with prognosis of HCC were mediated by the SHP-1/JAK2/STAT3 signaling. Conclusions: ZnAs@SiO2 NPs can effectively suppress tumor initiation, growth, metastasis, and inhibit stemness and EMT through regulation of SHP-1/JAK2/STAT3 signaling pathway in liver cancer cells in vitro and in vivo. Thus, ZnAs@SiO2 NPs have immense potential for HCC treatment in the future." @default.
• W2950240845 created "2019-06-27" @default.
• W2950240845 creator A5003620433 @default.
• W2950240845 creator A5010541804 @default.
• W2950240845 creator A5014160525 @default.
• W2950240845 creator A5022408293 @default.
• W2950240845 creator A5028491241 @default.
• W2950240845 creator A5030064573 @default.
• W2950240845 creator A5030172482 @default.
• W2950240845 creator A5038851564 @default.
• W2950240845 creator A5047901127 @default.
• W2950240845 creator A5048411184 @default.
• W2950240845 creator A5050656056 @default.
• W2950240845 creator A5057339247 @default.
• W2950240845 creator A5057356935 @default.
• W2950240845 creator A5078867858 @default.
• W2950240845 date "2019-01-01" @default.
• W2950240845 modified "2023-10-16" @default.
• W2950240845 title "ZnAs@SiO₂ nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling" @default.
• W2950240845 cites W1963920328 @default.
• W2950240845 cites W1963965802 @default.
• W2950240845 cites W1971095929 @default.
• W2950240845 cites W1974875036 @default.
• W2950240845 cites W1998948328 @default.
• W2950240845 cites W2023546573 @default.
• W2950240845 cites W2031549638 @default.
• W2950240845 cites W2033638867 @default.
• W2950240845 cites W2045207445 @default.
• W2950240845 cites W2050212958 @default.
• W2950240845 cites W2050394736 @default.
• W2950240845 cites W2051024356 @default.
• W2950240845 cites W2051055358 @default.
• W2950240845 cites W2052096100 @default.
• W2950240845 cites W2053271495 @default.
• W2950240845 cites W2063211899 @default.
• W2950240845 cites W2078480329 @default.
• W2950240845 cites W2100559817 @default.
• W2950240845 cites W2102449174 @default.
• W2950240845 cites W2104546896 @default.
• W2950240845 cites W2122306081 @default.
• W2950240845 cites W2123724074 @default.
• W2950240845 cites W2130552015 @default.
• W2950240845 cites W2136405488 @default.
• W2950240845 cites W2155685502 @default.
• W2950240845 cites W2163113687 @default.
• W2950240845 cites W2231802161 @default.
• W2950240845 cites W2260620286 @default.
• W2950240845 cites W2333009424 @default.
• W2950240845 cites W2344409258 @default.
• W2950240845 cites W2512891139 @default.
• W2950240845 cites W2546275879 @default.
• W2950240845 cites W2606001457 @default.
• W2950240845 cites W2746031475 @default.
• W2950240845 cites W2754890747 @default.
• W2950240845 cites W2763367287 @default.
• W2950240845 cites W2765897517 @default.
• W2950240845 cites W2789534015 @default.
• W2950240845 cites W2795151620 @default.
• W2950240845 cites W2797144689 @default.
• W2950240845 cites W2800317066 @default.
• W2950240845 cites W2802173235 @default.
• W2950240845 cites W2804537586 @default.
• W2950240845 cites W2889646458 @default.
• W2950240845 cites W2904520705 @default.
• W2950240845 cites W3148931375 @default.
• W2950240845 cites W4211233744 @default.
• W2950240845 doi "https://doi.org/10.7150/thno.32462" @default.
• W2950240845 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6599649" @default.
• W2950240845 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31285768" @default.
• W2950240845 hasPublicationYear "2019" @default.
• W2950240845 type Work @default.
• W2950240845 sameAs 2950240845 @default.
• W2950240845 citedByCount "45" @default.
• W2950240845 countsByYear W29502408452019 @default.
• W2950240845 countsByYear W29502408452020 @default.
• W2950240845 countsByYear W29502408452021 @default.
• W2950240845 countsByYear W29502408452022 @default.
• W2950240845 countsByYear W29502408452023 @default.
• W2950240845 crossrefType "journal-article" @default.
• W2950240845 hasAuthorship W2950240845A5003620433 @default.
• W2950240845 hasAuthorship W2950240845A5010541804 @default.
• W2950240845 hasAuthorship W2950240845A5014160525 @default.
• W2950240845 hasAuthorship W2950240845A5022408293 @default.
• W2950240845 hasAuthorship W2950240845A5028491241 @default.
• W2950240845 hasAuthorship W2950240845A5030064573 @default.
• W2950240845 hasAuthorship W2950240845A5030172482 @default.
• W2950240845 hasAuthorship W2950240845A5038851564 @default.
• W2950240845 hasAuthorship W2950240845A5047901127 @default.
• W2950240845 hasAuthorship W2950240845A5048411184 @default.
• W2950240845 hasAuthorship W2950240845A5050656056 @default.
• W2950240845 hasAuthorship W2950240845A5057339247 @default.
• W2950240845 hasAuthorship W2950240845A5057356935 @default.
• W2950240845 hasAuthorship W2950240845A5078867858 @default.
• W2950240845 hasBestOaLocation W29502408451 @default.
• W2950240845 hasConcept C121608353 @default.
• W2950240845 hasConcept C126322002 @default.
• W2950240845 hasConcept C142724271 @default.
• W2950240845 hasConcept C150903083 @default.

• next